CY2017048I1 - Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης - Google Patents

Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης

Info

Publication number: CY2017048I1
Authority: CY; Cyprus
Prior art keywords: stavrosporine; derivatives; new pharmaceutical; pharmaceutical uses; new
Prior art date: 2003-06-18

Application number

CY2017048C

Other languages

English (en)

Other versions

CY2017048I2 (el

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-18

Filing date

2017-12-22

Publication date

2018-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017048(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-22 Application filed by Novartis Ag filed Critical Novartis Ag

2018-09-05 Publication of CY2017048I2 publication Critical patent/CY2017048I2/el

2018-09-05 Publication of CY2017048I1 publication Critical patent/CY2017048I1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CY2017048C 2003-06-18 2017-12-22 Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης CY2017048I1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47957503P	2003-06-18	2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en)	2003-06-18	2004-06-17	New pharmaceutical uses of staurosporine derivatives
EP04740016A EP1638574B1 (en)	2003-06-18	2004-06-17	New pharmaceutical uses of staurosporine derivatives

Publications (2)

Publication Number	Publication Date
CY2017048I2 CY2017048I2 (el)	2018-09-05
CY2017048I1 true CY2017048I1 (el)	2018-09-05

Family

ID=33539193

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20101100627T CY1110179T1 (el)	2003-06-18	2010-07-06	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
CY2017048C CY2017048I1 (el)	2003-06-18	2017-12-22	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20101100627T CY1110179T1 (el)	2003-06-18	2010-07-06	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης

Country Status (23)

Country	Link
US (2)	US8575146B2 (el)
EP (1)	EP1638574B1 (el)
JP (2)	JP5057780B2 (el)
CN (2)	CN100457111C (el)
AT (1)	ATE464052T1 (el)
AU (1)	AU2004248909B2 (el)
BE (1)	BE2017C067I2 (el)
BR (1)	BRPI0411563B8 (el)
CA (2)	CA2527703C (el)
CY (2)	CY1110179T1 (el)
DE (1)	DE602004026578D1 (el)
DK (1)	DK1638574T3 (el)
ES (1)	ES2344700T3 (el)
FR (1)	FR17C1063I2 (el)
HU (1)	HUS000503I2 (el)
LU (1)	LUC00055I9 (el)
MX (1)	MXPA05013722A (el)
NL (1)	NL300917I2 (el)
PL (1)	PL1638574T3 (el)
PT (1)	PT1638574E (el)
SI (1)	SI1638574T1 (el)
TW (1)	TWI324604B (el)
WO (1)	WO2004112794A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
JP4762150B2 (ja)	2003-11-18	2011-08-31	ノバルティスアーゲー	Ｋｉｔの変異体の阻害剤
WO2005115385A1 (en) *	2004-05-24	2005-12-08	Ab Science	Use of c-kit inhibitors for treating acne
US20090054358A1 (en) *	2004-07-19	2009-02-26	The John Hopkins University	Flt3 inhibitors for immune suppression
MX2007001155A (es) *	2004-07-29	2007-08-14	Creabilis Therapeutics Spa	Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
PL1879585T3 (pl) *	2005-05-02	2013-08-30	Novartis Ag	Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej
RU2429848C2 (ru) *	2005-07-20	2011-09-27	Петер ФАЛЕНТ	Композиции для лечения системного мастоцитоза
AU2006313724B2 (en) *	2005-11-14	2010-12-23	Universitat Zurich	Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) *	2008-01-23	2009-07-30	Universidad De Barcelona	Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
EP2662078A1 (en) *	2010-11-10	2013-11-13	National Jewish Health	Methods to Treat Allergic Conditions
US20210401859A1 (en)	2018-11-01	2021-12-30	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
US11325978B2 (en) *	2018-11-06	2022-05-10	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Compositions and methods for treating beta-globinopathies
US11839619B2 (en) *	2019-09-16	2023-12-12	The Regents Of The University Of California	Methods for treatment of pediatric systemic mastocytosis
KR102805013B1 (ko) *	2022-03-15	2025-05-09	국립해양생물자원관	스트렙토마이세스 속 snc087 균주 또는 이로부터 분리한 스타우로스포린을 유효성분으로 포함하는 비용종 예방 또는 치료용 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4639455A (en) *	1984-10-02	1987-01-27	Key Pharmaceuticals, Inc.	Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja)	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US5093330A (en) *	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en)	1990-08-07	2002-02-26	Peter D. Davis	Substituted pyrroles
DK0518468T3 (da) *	1991-05-09	2000-01-31	Neurim Pharma 1991	Melatoninholdige sammensætninger
AR004480A1 (es)	1995-04-06	1998-12-16	Amico Derin C D	Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
WO1997049406A1 (en)	1996-06-25	1997-12-31	Cephalon, Inc.	Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en)	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
WO1999062537A1 (en) *	1998-06-04	1999-12-09	The Rockefeller University	Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
GB9903547D0 (en) *	1999-02-16	1999-04-07	Novartis Ag	Organic compounds
ATE301661T1 (de) *	2000-12-08	2005-08-15	Ortho Mcneil Pharm Inc	Makroheterocyclische verbindungen als kinase inhibitoren
GB0108606D0 (en) *	2001-04-05	2001-05-23	Novartis Ag	Organic compounds
WO2003002109A2 (en) *	2001-06-29	2003-01-09	Ab Science	Use of tyrosine kinase inhibitors for treating autoimmune diseases
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
EP1441737B1 (en) *	2001-10-30	2006-08-09	Novartis AG	Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6998391B2 (en) *	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
CA2522712A1 (en) *	2003-04-18	2004-10-28	Kyowa Hakko Kogyo Co., Ltd.	Nerve regenerating drug
WO2004093910A1 (ja)	2003-04-22	2004-11-04	Astellas Pharma Inc.	ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
JP4762150B2 (ja)	2003-11-18	2011-08-31	ノバルティスアーゲー	Ｋｉｔの変異体の阻害剤

2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh not_active Expired - Lifetime
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 EP EP04740016A patent/EP1638574B1/en not_active Expired - Lifetime
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 CA CA2527703A patent/CA2527703C/en not_active Expired - Lifetime
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja not_active Expired - Lifetime
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de not_active Expired - Lifetime
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en not_active Expired
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en not_active Ceased
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active IP Right Cessation
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es not_active Expired - Lifetime
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active

Also Published As

Publication number	Publication date
PL1638574T3 (pl)	2010-09-30
LUC00055I1 (el)	2017-12-14
EP1638574A2 (en)	2006-03-29
LUC00055I9 (el)	2022-11-09
US20070299049A1 (en)	2007-12-27
EP1638574B1 (en)	2010-04-14
AU2004248909B2 (en)	2008-05-08
FR17C1063I2 (fr)	2019-05-03
DK1638574T3 (da)	2010-08-02
HK1095519A1 (zh)	2007-05-11
ES2344700T3 (es)	2010-09-03
LUC00055I2 (el)	2018-02-21
HUS000503I2 (hu)	2021-03-29
CN101164539A (zh)	2008-04-23
JP2006527727A (ja)	2006-12-07
TWI324604B (en)	2010-05-11
AU2004248909A1 (en)	2004-12-29
MXPA05013722A (es)	2006-03-08
ATE464052T1 (de)	2010-04-15
BRPI0411563B1 (pt)	2019-09-24
TW200512213A (en)	2005-04-01
DE602004026578D1 (de)	2010-05-27
NL300917I2 (nl)	2018-01-09
WO2004112794A3 (en)	2005-06-16
CY1110179T1 (el)	2015-01-14
JP5057780B2 (ja)	2012-10-24
US20130289018A1 (en)	2013-10-31
NL300917I1 (nl)	2017-12-12
CA2785950A1 (en)	2004-12-29
CA2527703C (en)	2012-10-23
CA2527703A1 (en)	2004-12-29
BRPI0411563B8 (pt)	2021-05-25
CN1805749A (zh)	2006-07-19
CY2017048I2 (el)	2018-09-05
PT1638574E (pt)	2010-07-14
BE2017C067I2 (el)	2023-08-09
HUS1700053I1 (hu)	2018-01-29
JP2012144572A (ja)	2012-08-02
WO2004112794A2 (en)	2004-12-29
SI1638574T1 (sl)	2010-08-31
CN100457111C (zh)	2009-02-04
US8575146B2 (en)	2013-11-05
FR17C1063I1 (el)	2018-02-16
BRPI0411563A (pt)	2006-08-01

Publication	Publication Date	Title
CY2017048I2 (el)	2018-09-05	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
CY2018005I2 (el)	2018-06-27	Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
ATE340782T1 (de)	2006-10-15	Piperidinbenzolsulfonamidderivate
ATE352550T1 (de)	2007-02-15	Chinazolinderivate
DK1682493T3 (da)	2009-04-20	Amidoacetonitrilderivater
NO20054224D0 (no)	2005-09-12	Nye 2-pyridinkarboksamidderivater
ATE499347T1 (de)	2011-03-15	Amidderivate
ATE395345T1 (de)	2008-05-15	Imidazol-4-yl-ethynyl-pyridin-derivate
IS2656B (is)	2010-08-15	Nýjar besímídasólafleiður
DK1587478T3 (da)	2013-10-21	Farmaceutisk sammensætning
DK1622612T3 (da)	2008-05-26	Farmaceutisk formulering af natriumsaltet af telmitarsan
DK1652843T3 (da)	2014-05-05	Amidderivater
NO20043937L (no)	2005-03-23	Anvendelse av vitamin D sammensetninger
ATE335729T1 (de)	2006-09-15	3h-chinazoline -4-on derivaten
ATE354365T1 (de)	2007-03-15	N-thiazol-2-yl-benzamid-derivate
ATE449064T1 (de)	2009-12-15	Amidoacetonitrilderivate
IS8045A (is)	2005-09-26	Púrín-6-ón-afleiður
NO20034952D0 (no)	2003-11-06	Farmasöytiske forbindelser
ATE499348T1 (de)	2011-03-15	Stabiler polymorph von bifeprunoxmesilat
NO20044164L (no)	2004-09-30	Farmasoytiske sammensetninger
DE112004001429D2 (de)	2006-04-13	Pharmazeutischer Wirkstoff
PT1467737E (pt)	2006-08-31	Composicao farmaceutica orodispersivel de piribedil
ITRM20030053A1 (it)	2004-08-11	Associazione di farmaci antidiabetici.
FI20030224A0 (fi)	2003-02-13	Uudet farmaseuttiset käytöt
DOP2003000794A (es)	2004-07-15	Nuevos compuestos farmaceuticos